Log in

NASDAQ:BBIOBridgeBio Pharma News Headlines

$28.39
-0.09 (-0.32 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$28.18
Now: $28.39
$30.15
50-Day Range
$27.20
MA: $30.42
$34.32
52-Week Range
$14.23
Now: $28.39
$48.36
Volume401,400 shs
Average Volume760,750 shs
Market Capitalization$3.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.6

Headlines

BridgeBio Pharma (NASDAQ BBIO) News Headlines

Source:
DateHeadline
BridgeBio Pharma (NASDAQ:BBIO) Releases  Earnings ResultsBridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results
americanbankingnews.com - August 12 at 11:14 AM
BridgeBio Pharma (NASDAQ:BBIO) Receives "Buy" Rating from HC WainwrightBridgeBio Pharma (NASDAQ:BBIO) Receives "Buy" Rating from HC Wainwright
americanbankingnews.com - August 12 at 9:50 AM
MyoKardia inks licensing pact for its oncology candidates with LianBio in ChinaMyoKardia inks licensing pact for its oncology candidates with LianBio in China
seekingalpha.com - August 11 at 4:34 PM
BridgeBio Pharma inks licensing pact for its oncology candidates with LianBio in ChinaBridgeBio Pharma inks licensing pact for its oncology candidates with LianBio in China
seekingalpha.com - August 11 at 4:34 PM
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBioBridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
finance.yahoo.com - August 11 at 4:34 PM
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business UpdateBridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update
finance.yahoo.com - August 11 at 4:34 PM
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Insider Sells 4,661 Shares of StockInsider Selling: BridgeBio Pharma (NASDAQ:BBIO) Insider Sells 4,661 Shares of Stock
americanbankingnews.com - August 6 at 12:58 AM
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 66,057 Shares of StockInsider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 66,057 Shares of Stock
americanbankingnews.com - August 6 at 12:12 AM
Notable Monday Option Activity: BBIO, PFGC, FIZZNotable Monday Option Activity: BBIO, PFGC, FIZZ
nasdaq.com - August 3 at 9:51 PM
Investors Buy Large Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO)Investors Buy Large Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO)
americanbankingnews.com - August 3 at 8:26 PM
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 5.3%BridgeBio Pharma (NASDAQ:BBIO) Trading Down 5.3%
www.americanbankingnews.com - July 31 at 8:19 PM
BridgeBio Pharma (NASDAQ:BBIO) Given Consensus Rating of "Hold" by AnalystsBridgeBio Pharma (NASDAQ:BBIO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 31 at 3:43 AM
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent GlioblastomaIvy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
finance.yahoo.com - July 28 at 7:50 AM
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 7%BridgeBio Pharma (NASDAQ:BBIO) Shares Up 7%
www.americanbankingnews.com - July 27 at 7:48 PM
Mid-stage study underway on BridgeBios infigratinib for bone growth disorderMid-stage study underway on BridgeBio's infigratinib for bone growth disorder
seekingalpha.com - July 15 at 8:44 AM
BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in AchondroplasiaBridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
finance.yahoo.com - July 15 at 8:44 AM
BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual MeetingBridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting
finance.yahoo.com - July 10 at 7:56 AM
BRIEF-Bridgebio Pharma Inc Files For Mixed Shelf Of Upto $350 MlnBRIEF-Bridgebio Pharma Inc Files For Mixed Shelf Of Upto $350 Mln
www.reuters.com - July 7 at 7:24 PM
Hedge Funds Are Nibbling On BridgeBio Pharma, Inc. (BBIO)Hedge Funds Are Nibbling On BridgeBio Pharma, Inc. (BBIO)
finance.yahoo.com - July 5 at 7:02 PM
Interesting BBIO Put And Call Options For February 2021Interesting BBIO Put And Call Options For February 2021
www.nasdaq.com - June 26 at 12:40 PM
How Covid is reshaping the way clinical drug trials get doneHow Covid is reshaping the way clinical drug trials get done
www.bizjournals.com - June 25 at 9:38 PM
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of DirectorsBridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors
finance.yahoo.com - June 24 at 7:51 AM
BridgeBio Pharma teams up with University of Florida in genetic diseasesBridgeBio Pharma teams up with University of Florida in genetic diseases
seekingalpha.com - June 18 at 8:35 AM
BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven DiseasesBridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases
finance.yahoo.com - June 18 at 8:35 AM
BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven DiseasesBridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases
finance.yahoo.com - June 18 at 8:35 AM
BridgeBios Innovative Development PhilosophyBridgeBio's Innovative Development Philosophy
www.thestreet.com - June 12 at 10:06 AM
BRIEF-BridgeBio Pharmas ML Bio Announces Dosing Of First Subject In Phase 1 Trial For Limb Girdle Muscular Dystrophy Type 2IBRIEF-BridgeBio Pharma's ML Bio Announces Dosing Of First Subject In Phase 1 Trial For Limb Girdle Muscular Dystrophy Type 2I
www.reuters.com - June 11 at 12:58 PM
Dosing underway in BridgeBios BBP-418 trial for muscular dystrophyDosing underway in BridgeBio's BBP-418 trial for muscular dystrophy
seekingalpha.com - June 11 at 12:58 PM
BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
finance.yahoo.com - June 11 at 7:58 AM
Tracking Ole Andreas Halvorsens Viking Global Portfolio - Q1 2020 UpdateTracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2020 Update
seekingalpha.com - June 8 at 12:42 PM
BRIEF-Bridgebio Pharma’S Qed Therapeutics Presents Data On Infigratinib In Cholangiocarcinoma And Urothelial CarcinomaBRIEF-Bridgebio Pharma’S Qed Therapeutics Presents Data On Infigratinib In Cholangiocarcinoma And Urothelial Carcinoma
www.reuters.com - June 6 at 1:03 PM
BridgeBio Pharma (BBIO) Investor Presentation - SlideshowBridgeBio Pharma (BBIO) Investor Presentation - Slideshow
seekingalpha.com - May 29 at 1:08 PM
BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific ProgramBridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
finance.yahoo.com - May 29 at 9:27 AM
21 Risky Stocks That Might Have Borrowed More Than Is Good For Them21 Risky Stocks That Might Have Borrowed More Than Is Good For Them
finance.yahoo.com - May 19 at 10:21 AM
BridgeBio Pharma EPS misses by $0.07BridgeBio Pharma EPS misses by $0.07
seekingalpha.com - May 13 at 8:36 PM
BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business UpdateBridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update
finance.yahoo.com - May 13 at 8:36 PM
BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership AppointmentsBridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments
finance.yahoo.com - May 13 at 8:36 PM
BridgeBio Pharmas QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in AchondroplasiaBridgeBio Pharma's QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia
www.benzinga.com - May 11 at 6:13 PM
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in AchondroplasiaBridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia
finance.yahoo.com - May 11 at 6:13 PM
How Many BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Did Insiders Buy, In The Last Year?How Many BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Did Insiders Buy, In The Last Year?
finance.yahoo.com - April 28 at 11:17 AM
Why BridgeBio (BBIO) Stock Might be a Great PickWhy BridgeBio (BBIO) Stock Might be a Great Pick
finance.yahoo.com - April 8 at 2:01 PM
Is BridgeBio Pharma, Inc. (BBIO) A Good Stock To Buy?Is BridgeBio Pharma, Inc. (BBIO) A Good Stock To Buy?
finance.yahoo.com - April 7 at 1:59 AM
BridgeBio Pharma Inc.BridgeBio Pharma Inc.
www.barrons.com - April 2 at 3:57 PM
BridgeBio Pharmas QED Therapeutics...BridgeBio Pharma's QED Therapeutics...
www.benzinga.com - March 12 at 9:08 AM
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic AlterationsBridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
finance.yahoo.com - March 12 at 9:08 AM
BridgeBio prices upsized convertible debt offeringBridgeBio prices upsized convertible debt offering
seekingalpha.com - March 5 at 8:38 AM
BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior NotesBridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes
finance.yahoo.com - March 5 at 1:04 AM
BridgeBio launches $350M convertible debt offeringBridgeBio launches $350M convertible debt offering
seekingalpha.com - March 4 at 12:15 PM
Advances in Treatments Are Leading to a Decline in Deaths from CancerAdvances in Treatments Are Leading to a Decline in Deaths from Cancer
www.marketwatch.com - March 4 at 12:15 PM
BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior NotesBridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes
finance.yahoo.com - March 4 at 7:15 AM
This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.